Literature DB >> 20019986

Role of lymphadenectomy for invasive bladder cancer.

Faysal A Yafi1, Wassim Kassouf.   

Abstract

Radical cystectomy with lymph node dissection remains the standard of care in the treatment of muscle-invasive and refractory non-invasive bladder cancer. Over the past decade, the extent of lymphadenectomy has varied to include dissection up to the common iliac vessels and aortic bifurcation proximally (may also extend up to the level of the inferior mesenteric artery), the genitofemoral nerve laterally, the circumflex iliac vein and lymph node of Cloquet distally, and the hypogastric vessels posteriorly (obturator fossa, presciatic nodes bilaterally and the presacral lymph nodes over the sacral promontory). Evidence supports the role of lymphadenectomy as both a therapeutic and prognostic variable in patients with invasive bladder cancer. We review the literature regarding the role and extent of lymphadenectomy, as well as its impact on patient outcomes.

Entities:  

Year:  2009        PMID: 20019986      PMCID: PMC2792445          DOI: 10.5489/cuaj.1197

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  37 in total

1.  Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens.

Authors:  B H Bochner; H W Herr; V E Reuter
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

2.  Superiority of ratio based lymph node staging for bladder cancer.

Authors:  Harry W Herr
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

3.  Indications for early cystectomy.

Authors:  John P Stein
Journal:  Urology       Date:  2003-10       Impact factor: 2.649

4.  Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy.

Authors:  Wassim Kassouf; Dan Leibovici; Mark F Munsell; Colin P Dinney; H Barton Grossman; Ashish M Kamat
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

5.  Cancer in Canada in 2008.

Authors:  Loraine D Marrett; Prithwish De; Parisa Airia; Dagny Dryer
Journal:  CMAJ       Date:  2008-11-18       Impact factor: 8.262

6.  Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy.

Authors:  Stephan Madersbacher; Werner Hochreiter; Fiona Burkhard; George N Thalmann; Hansjörg Danuser; Regula Markwalder; Urs E Studer
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

7.  Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic.

Authors:  K Weingärtner; A Ramaswamy; A Bittinger; E W Gerharz; D Vöge; H Riedmiller
Journal:  J Urol       Date:  1996-12       Impact factor: 7.450

8.  The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy.

Authors:  Jonathan L Wright; Daniel W Lin; Michael P Porter
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

9.  Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.

Authors:  Kenneth Steven; Asger L Poulsen
Journal:  J Urol       Date:  2007-08-14       Impact factor: 7.450

10.  Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density.

Authors:  John P Stein; Jie Cai; Susan Groshen; Donald G Skinner
Journal:  J Urol       Date:  2003-07       Impact factor: 7.450

View more
  2 in total

1.  Lymphadenectomy in management of invasive bladder cancer.

Authors:  Ramy F Youssef; Ganesh V Raj
Journal:  Int J Surg Oncol       Date:  2011-06-16

2.  miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.

Authors:  Ye Lei; Bin Li; Shiyu Tong; Lin Qi; Xiheng Hu; Yunbo Cui; Zengbo Li; Wei He; Xiongbing Zu; Zhi Wang; Minfeng Chen
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.